| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4704 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate |
2012-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b340e3e1c199089bfba33248b03103f |
| publicationDate |
2012-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2488028-A |
| titleOfInvention |
mTOR mutants as biomarkers for mTOR inhibitor treatment |
| abstract |
A method of selection of a patient, who is a candidate for treatment with an mTOR inhibitor (mammalian target of rapamycin inhibitor), whereby to predict an increased or decreased likelihood of response to an mTOR inhibitor, wherein the amino acid at position 1977 of the mTOR protein is determined as being lysine or an adenine is determined as being present at position 5930 of the mTOR gene. The invention provides a method for determining the sequence of mTOR. The method also provides ARMS primers optimised for determining the sequence of mTOR. The invention also provides a diagnostic kit, comprising an ARMS primer. The use of mTOR inhibitors such as rapamycin (sirolimus) is claimed, particularly in cancer treatments. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10610521-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016067229-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2014229108-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014184734-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2521913-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2521913-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905665-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9249466-B2 |
| priorityDate |
2011-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |